Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next-generation targeted therapies for improving patient treatment options.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 04/25/23 | $38,000,000 | Series A+ |
ABio-X Delta Capital Eight Roads  F-Prime Capital Partners Trinity Innovation Fund | undisclosed |
